Latest Whitepapers

Developing mRNA-based therapeutics is complex work, requiring highly skilled scientists, high-tech microfluidics platforms and sophisticated analytical equipment, and of course the mRNA itself.

Amidst the life science industry’s digital transformation, new and established companies have pioneered innovative ways to harness data and technology across the drug development lifecycle.

This whitepaper highlights the recent developments and performance of three modular benchtop solutions for the high-performance quantitation and kinetics characterization of proteins and their small molecule interactions.

This whitepaper highlights the features and capabilities of a novel system for streamlining affinity analysis for rapid lead molecule screening.

Active cell therapy drugs represent the latest in cancer treatment. Of these, chimeric antigen receptor (CAR) cell modalities are considered the most successful.

Chemical supply chain issues can have real, quantifiable impacts on biomanufacturers. While the efficient management of storage and inventory can help to reduce risk, it can also prove resource intensive and increase the total cost of ownership.

Innovation is key for any biopharmaceutical and biotechnology company. Whilst the demand for infectious disease prevention continues to grow, so does the pressure on these companies to deliver innovative solutions.

Process development teams need detailed information, via a platform that delivers short gradients to allow the required sample throughput to detect HCPs in a low sub-ppm range.

The EU GMP Annex 1 provides specific guidance on the manufacture of sterile medicinal products. Though it is a European guide for manufacturing, EU GMP Annex 1’s impact is global. So how does the latest revision affect you?

CRISPR/Cas9 has revolutionized the field of genome editing by increasing the efficiency, multiplex capability and ease of use like never before.